OBJECTIVE: To determine if care concordant with 2009 Schizophrenia Patient Outcomes Research Team (PORT) pharmacological recommendations for schizophrenia is associated with decreased mortality. METHODS: We conducted a retrospective cohort study of adult Maryland Medicaid beneficiaries with schizophrenia and any antipsychotic use from 1994 to 2004 (N = 2132). We used Medicaid pharmacy data to measure annual and average antipsychotic continuity, to calculate chlorpromazine (CPZ) dosing equivalents, and to examine anti-Parkinson medication use. Cox proportional hazards regression models were used to examine the relationship between antipsychotic continuity, antipsychotic dosing, and anti-Parkinson medication use and mortality. RESULTS: Annual antipsychotic continuity was associated with decreased mortality. Among patients with annual continuity greater than or equal to 90%, the hazard ratio [HR] for mortality was 0.75 (95% confidence interval [CI] 0.57-0.99) compared with patients with annual medication possession ratios (MPRs) of less than 10%. The HRs for mortality associated with continuous annual and average antipsychotic continuity were 0.75 (95% CI 0.58-0.98) and 0.84 (95% CI 0.58-1.21), respectively. Among users of first-generation antipsychotics, doses greater than or equal to 1500 CPZ dosing equivalents were associated with increased risk of mortality (HR 1.88, 95% CI 1.10-3.21), and use of anti-Parkinson medication was associated with decreased risk of mortality (HR 0.72, 95% CI 0.55-0.95). Mental health visits were also associated with decreased mortality (HR 0.96, 95% CI 0.93-0.98). CONCLUSIONS: Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia. Adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence to the PORT guidelines should be considered.
OBJECTIVE: To determine if care concordant with 2009 SchizophreniaPatient Outcomes Research Team (PORT) pharmacological recommendations for schizophrenia is associated with decreased mortality. METHODS: We conducted a retrospective cohort study of adult Maryland Medicaid beneficiaries with schizophrenia and any antipsychotic use from 1994 to 2004 (N = 2132). We used Medicaid pharmacy data to measure annual and average antipsychotic continuity, to calculate chlorpromazine (CPZ) dosing equivalents, and to examine anti-Parkinson medication use. Cox proportional hazards regression models were used to examine the relationship between antipsychotic continuity, antipsychotic dosing, and anti-Parkinson medication use and mortality. RESULTS: Annual antipsychotic continuity was associated with decreased mortality. Among patients with annual continuity greater than or equal to 90%, the hazard ratio [HR] for mortality was 0.75 (95% confidence interval [CI] 0.57-0.99) compared with patients with annual medication possession ratios (MPRs) of less than 10%. The HRs for mortality associated with continuous annual and average antipsychotic continuity were 0.75 (95% CI 0.58-0.98) and 0.84 (95% CI 0.58-1.21), respectively. Among users of first-generation antipsychotics, doses greater than or equal to 1500 CPZ dosing equivalents were associated with increased risk of mortality (HR 1.88, 95% CI 1.10-3.21), and use of anti-Parkinson medication was associated with decreased risk of mortality (HR 0.72, 95% CI 0.55-0.95). Mental health visits were also associated with decreased mortality (HR 0.96, 95% CI 0.93-0.98). CONCLUSIONS: Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia. Adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence to the PORT guidelines should be considered.
Authors: Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs Journal: Schizophr Bull Date: 2004 Impact factor: 9.306
Authors: Cheryl Enger; Lisa Weatherby; Robert F Reynolds; Dale B Glasser; Alexander M Walker Journal: J Nerv Ment Dis Date: 2004-01 Impact factor: 2.254
Authors: Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Stanley N Caroff; Shirley H Leong; Daisy Ng-Mak; E Cabrina Campbell; Rosalind M Berkowitz; Krithika Rajagopalan; Chien-Chia Chuang; Antony Loebel Journal: Community Ment Health J Date: 2017-12-28
Authors: Bernadette A Cullen; Katrina Rodriguez; William W Eaton; Ramin Mojtabai; Tara Von Mach; Michele L Ybarra Journal: Psychiatry Res Date: 2020-07-29 Impact factor: 3.222
Authors: Nancy H Liu; Gail L Daumit; Tarun Dua; Ralph Aquila; Fiona Charlson; Pim Cuijpers; Benjamin Druss; Kenn Dudek; Melvyn Freeman; Chiyo Fujii; Wolfgang Gaebel; Ulrich Hegerl; Itzhak Levav; Thomas Munk Laursen; Hong Ma; Mario Maj; Maria Elena Medina-Mora; Merete Nordentoft; Dorairaj Prabhakaran; Karen Pratt; Martin Prince; Thara Rangaswamy; David Shiers; Ezra Susser; Graham Thornicroft; Kristian Wahlbeck; Abe Fekadu Wassie; Harvey Whiteford; Shekhar Saxena Journal: World Psychiatry Date: 2017-02 Impact factor: 49.548
Authors: Richard D Hayes; Johnny Downs; Chin-Kuo Chang; Richard G Jackson; Hitesh Shetty; Matthew Broadbent; Matthew Hotopf; Robert Stewart Journal: Schizophr Bull Date: 2014-08-25 Impact factor: 9.306
Authors: Carlos De Las Cuevas; Jose de Leon; Wenceslao Peñate; Moisés Betancort Journal: Patient Prefer Adherence Date: 2017-03-28 Impact factor: 2.711
Authors: Dukyong Yoon; Inwhee Park; Martijn J Schuemie; Man Young Park; Ju Han Kim; Rae Woong Park Journal: PLoS One Date: 2013-10-10 Impact factor: 3.240